Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | KDM5A | P29375 | 3/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2078513 | 1.00 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| Cyclohexane SCHEMBL11567704 | 1.00 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL80440 | 1.00 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL1573054 | 1.00 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL25310908 | 0.97 | SIGMAR1 (0.60) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL1007122 | 0.97 | SIGMAR1 (0.60) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL1006136 | 0.97 | SIGMAR1 (0.60) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL330182 | 0.97 | SIGMAR1 (0.60) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL1006265 | 0.97 | SIGMAR1 (0.60) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL1006966 | 0.97 | SIGMAR1 (0.60) | SIGMAR1CYP1A2EPHX1KDM5APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| WO-2007057775-A1 | SPIROPIPERIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2007-05-24 | — | — | WO | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-20030162662-A1 | 2-Phenyl-2h-pyridazine-3-ones | BASF AKTIENGESELLSCHAFT (DE) | 2003-08-28 | — | — | US | disclosed |
| US-3962105-A | LUBRICATING COMPOSITIONS | THE LUBRIZOL CORPORATION (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | SIGMAR1 234/4885CYP1A2 659/4885EPHX1 4071/4885 |
| US-20030162662-A1 | 2-Phenyl-2h-pyridazine-3-ones | CNPY2, CBR3, CBR1 | SIGMAR1 404/4885CYP1A2 35/4885EPHX1 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.